B1SX34.SA Boston Scientific Corporation
- Market cap
- BRL 365B
- P/E
- 20.4x
- P/B
- 3.42x
- ROE
- 18.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is B1SX34.SA undervalued?
Graham numberB1SX34.SA trades 75.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Boston Scientific Corporation fundamental analysis
No fundamental analysis for Boston Scientific Corporation yet.
Boston Scientific Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pa…
Full company profileBoston Scientific Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Boston Scientific Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 9.82B | 10.7B | 9.91B | 11.9B | 12.7B | 14.2B | 16.7B | 20.1B | 21.3B |
| Gross Profit | 6.94B | 7.55B | 6.40B | 8.13B | 8.75B | 9.92B | 11.5B | 13.9B | 14.9B |
| Operating Income | 1.66B | 1.74B | 684M | 1.82B | 1.46B | 2.54B | 2.60B | 3.59B | 4.64B |
| EBITDA | 2.56B | 2.17B | 1.41B | 2.51B | 2.75B | 3.45B | 3.86B | 5.10B | 6.23B |
| Net Income | 1.67B | 4.70B | -82.0M | 1.04B | 698M | 1.59B | 1.85B | 2.90B | 4.50B |
| EPS | 1.21 | 3.37 | -0.06 | 0.73 | 0.49 | 1.09 | 1.26 | 1.95 | 3.11 |
| Balance Sheet | |||||||||
| Total Assets | 21.0B | 30.6B | 30.8B | 32.2B | 32.5B | 35.1B | 39.4B | 43.7B | 45.2B |
| Total Liabilities | 12.3B | 16.7B | 15.5B | 15.6B | 14.9B | 15.6B | 17.4B | 19.4B | 20.0B |
| Shareholders' Equity | 8.73B | 13.9B | 15.3B | 16.6B | 17.6B | 19.3B | 21.8B | 24.2B | 24.9B |
| Cash & Short-term Investments | 146M | 217M | 1.73B | 1.93B | 928M | 865M | 414M | 1.97B | 539M |
| Cash Flow | |||||||||
| Operating Cash Flow | 310M | 1.84B | 1.51B | 1.87B | 1.53B | 2.50B | 3.43B | 4.53B | 3.64B |
| Capital Expenditure | 316M | 461M | 376M | 554M | 588M | 800M | 790M | 876M | 4.20B |
| Free Cash Flow | -6.00M | 1.38B | 1.13B | 1.32B | 914M | 1.70B | 2.37B | 3.40B | -560M |
| Ratios | |||||||||
| ROE | 19.2% | 33.9% | -0.5% | 6.3% | 4.0% | 8.3% | 8.5% | 12.0% | 18.0% |
| ROA | 8.0% | 15.4% | -0.3% | 3.2% | 2.1% | 4.5% | 4.7% | 6.6% | 9.9% |
| Net Profit Margin | 17.0% | 43.8% | -0.8% | 8.8% | 5.5% | 11.2% | 11.1% | 14.4% | 21.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Boston Scientific Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 28.0M | 0.02 | 1.8% |
| 2022 | USD 55.0M | 0.04 | 7.9% |
| 2021 | USD 55.0M | 0.04 | 5.3% |
| 2020 | USD 28.0M | 0.02 | - |
| 2019 | BRL 28.0M | 0.02 | 0.6% |
| 2018 | BRL 28.0M | 0.02 | 1.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Jul 27, 2026.
Who owns Boston Scientific Corporation
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 5.80B
- Free float 5.78B
Boston Scientific Corporation company profile
- Company name
- Boston Scientific Corporation
- Ticker
- B1SX34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 59,000
- Fiscal year end
- December
- Address
- 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234
- Phone
- 508 683 4000
- Website
- bostonscientific.com
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Boston Scientific Corporation management
10- Mr. Michael F. MahoneyChairman, President & CEO · born 1965
- Mr. Jonathan R. MonsonExecutive VP & CFO · born 1974
- Mr. Vance R. Brown J.D.EVP, General Counsel & Corporate Secretary · born 1970
- Mr. Joseph M. FitzgeraldExecutive VP & Group President of Cardiovascular · born 1964
- Mr. Arthur Crosswell ButcherExecutive VP and Group President of MedSurg & Asia Pacific · born 1971
- Mr. Paudie O'ConnorExecutive Vice President of Global Operations · born 1968
- Ms. Emily M. WoodworthSenior VP, Global Controller & Chief Accounting Officer · born 1978
- Mr. Adam SmithGeneral Manager of Global Sales & Marketing
- Ms. Miriam O'sullivanSenior VP & Chief Human Resources Officer · born 1981
- Ms. Brenda BeckerSenior Vice President of Global Government Affairs · born 1960